

# **Syncope**

## **Current Approaches to Diagnosis and Management**

# Syncope

- ♦ **Common & important medical problem**
- ♦ **1% of all hospital admissions**
- ♦ **3% of all ER visits**

Lipsitz LA. Queensland J Med. 1985;55(216):45-54.

Savage DD. Stroke. 1985;16(4):626-629.

# **Syncope in Elderly Population**

- ♦ **Incidence 6%**
- ♦ **Recurrence 30%**

# Causes of Syncope



# **Arrhythmic Causes of Syncope**

- ♦ **Sick sinus syndrome**
- ♦ **Sinus bradycardia or asystole**
- ♦ **Complete AV block**
- ♦ **Mobitz II AV block**
- ♦ **Hypotensive ventricular tachycardia**
- ♦ **Ventricular fibrillation**
- ♦ **Hypotensive supraventricular tachycardia**

# **Nonarrhythmic Cardiac Causes of Syncope**

- ♦ **Aortic stenosis**
- ♦ **Pulmonary hypertension**
- ♦ **Acute myocardial infarction**
- ♦ **Pulmonary embolus**
- ♦ **Dissecting aortic aneurysm**
- ♦ **Carotid sinus hypersensitivity**
- ♦ **Neurally-mediated syncope**

# **Noncardiac Causes of Syncope**

- ♦ **Transient ischemic attack**
- ♦ **Seizure disorder**
- ♦ **Subclavian steal**
- ♦ **Orthostatic hypotension**
- ♦ **Vasovagal syncope**
- ♦ **Conversion reaction**
- ♦ **Situational syncope (cough, micturition, defecation)**
- ♦ **Drug-induced**
- ♦ **Anemia**
- ♦ **Hypoglycemia**

# **Common Causes of Syncope**

- ♦ **In young**
  - **Vasovagal syncope**
  - **Neurally-mediated syncope**
- ♦ **In elderly**
  - **Sick sinus syndrome**
  - **AV block**
  - **Ventricular tachycardia**
  - **Drugs**



# Drugs Causing Syncope

- ♦ **Hypotensive agents**
  - **Nitrates**
  - **Antihypertensive agents**
    - **Beta blockers**
    - **Calcium channel blockers**
    - **ACE inhibitors**
- ♦ **Beta blockers**
- ♦ **Antiarrhythmics**
- ♦ **Psychotherapeutic drugs**
- ♦ **Hypoglycemic agents**
- ♦ **Illicit drugs/alcohol**

# **Mechanism of Syncope from Antiarrhythmic Agents**

- ♦ **Proarrhythmia**
- ♦ **Suppression of sinus node function**
- ♦ **Exacerbation of conduction disease**

# **Diagnostic Tests in Work-up of Syncope**

- ♦ **History & physical**
- ♦ **ECG**
- ♦ **Holter**
- ♦ **Echo/doppler**
- ♦ **EP study**
- ♦ **Tilt table testing**
- ♦ **Event recorder**
- ♦ **Insertable loop recorder**
- ♦ **Neurologic evaluation**
- ♦ **Psychologic evaluation**

**Of all tests for syncope, a thorough history & physical exam has the highest diagnostic yield.**

# **History for Syncope Should Include:**

- ♦ **Medication use (prescribed and over-the-counter)**
- ♦ **Assessment for hyperventilation or multiple somatic complaints, which might suggest psychiatric syncope**
- ♦ **Assessment for possible cardiac or neurologic disease**
- ♦ **Distinction between mechanical fall, vertigo, orthostatic hypotension and true syncope**

# **Physical Exam for Syncope Should Include:**

- ♦ **Orthostatic vital signs**
- ♦ **Examination for carotid disease**
- ♦ **Carotid sinus massage**

# **Seizure Activities Common in Syncope**

- ♦ **May not be neurological in origin**
- ♦ **May be 2° to low CNS blood flow from hypotension**

# **Value of ECG in Evaluating Syncope**

## **Identifies:**

- ♦ **Abnormalities suggestive of previous MI or underlying ischemia**
- ♦ **Rhythm abnormalities including AV block**
- ♦ **Bundle branch block**
- ♦ **Prolonged QT interval**



# **Value of Holter in Syncope Work-up**

- ♦ **Gibson, et al., retrospectively analyzed 7,364 patients undergoing 24-hour Holter during 5-year period.**
  - **Of these, 21% had been referred because of syncope.**

# Findings of Retrospective Holter Analysis in Syncope

## Yield:

- ♦ **Arrhythmia-related symptoms 2%**  
**(syncope/near syncope)**
- ♦ **Syncope symptoms 15%**  
**(no arrhythmia)**

# **Value of Holter in Syncope**


**Incremental yield with increased duration of Holter monitoring to 48 hours but no additional yield after 72 hours**

# **Value of Signal-Averaged ECG in Syncope**

**In a prospective study of patients referred to EP study for unexplained syncope, among patients with...**

- ♦ Inducible VT, 89% had late potentials**
- ♦ Noninducible VT, 0% had late potentials**


# Value of Event Recorder in Syncope



**\*Asterisk  
denotes event  
marker**

**Linzer M. Am J Cardiol. 1990;66:214-219.**

# Value of Event Recorder in Syncope



**\*Asterisk  
denotes event  
marker**

**Linzer M. Am J Cardiol. 1990;66:214-219.**

# **Value of EP Study in Syncope**

## **Diagnostically helpful findings at EP study:**

- ♦ **Markedly prolonged sinus node recovery time**
- ♦ **Markedly prolonged HV interval**
- ♦ **Infra-Hisian block**
- ♦ **Inducible VT**
- ♦ **Inducible SVT with associated hypotension**

# Diagnostic Yield (%) of Individual Tests in Work-up of Syncope


Author (N)	% With Clinical Setting	Recurrent Syncope	Neuro- H&P	ECG	Holter	CSM	EPS	logic	Other	Total
Eagle (100)	Inpatient	33	52	—	3	—	0	2	4	61
Day (198)	ER	37	73	2	2	—	—	9	—	87
Silverstein (108)	MICU	—	39	—	7.5	—	—	—	6.5	53
Kapoor (204) (1983)	In- and outpatient	68	25	6	14	—	1.5	0.5	5	52
Martin (170)*	ER	—	53	1	3	—	—	5	—	62
Kapoor (433) (1990)*	All	49	32	7	13	1	2	1	3	41

\*Prospective study




# Diagnostic Yield in Unexplained Syncope: A Tertiary Center Experience

86 patients with  
unexplained syncope



# Findings and Treatment of Syncope Patients with Abnormal EP Study

Findings in EP-positive patients (N = 29)




# Frequency (%) of Various Causes of Syncope

Author (N)	Vasovagal Unknown	Neurologic	Cardiac				Other
			Nonarrhythmic	Bradycardia	Tachycardia		
Eagle (100)	31	6	8	5	7	4	39
Day (198)	40	32	3	2.5	2.5	7	13
Silverstein (108)	4.5	4.5	9	9	18	8	47
Kapoor (204) (1983)	19	3	6	9	11	4	48
Martin (170)	45	9	0.5	0.5	3	4	38
Kapoor (433) (1990)	26	4	6	7	13	3	41

Chang-Sing P. Cardiol Clinics. 1991;9(4):641-651.

# Risk of Mortality from Syncope Based on Outcome of EP Study



Bass EB. Am J Cardiol. 1988;62:1186-1191.

# Risk of Mortality from Various Causes of Syncope

Author (N)	Mean Follow-Up Period (Months)	Mortality at Follow-up (%)		
		Cardiac Cause of Syncope	Noncardiac Cause of Syncope	Unknown
Day (198)	12	33		
Silverstein (108)	12	19	6	6
Kapoor (204) (1983)	12	30	12	6
Martin (170)	6	30	1	1.5
Kapoor (433) (1990)	12	26	8	6
	60	50	31	24

# **Risk of Mortality from Various Causes of Syncope**

**Mortality risk much higher (mean 30%) if syncope is due to cardiac cause.**

# **Tilt Table Test for Syncope**

- ♦ **Used to test for neurally-mediated syncope**
- ♦ **Measure heart rate and blood pressure in supine & 70° head-up tilt positions**
- ♦ **Isoproterenol infusion often added**

# **Tilt Table Test for Syncope**

**Abnormal responses seen during positive tilt test:**


- ♦ **Hypotension**
- ♦ **Bradycardia (sinus, junctional, or AV nodal block)**
- ♦ **Asystole**




# **Classification of Abnormal Responses to Tilt Table Testing**

- ♦ **Cardio-inhibitory (mainly bradycardia)**
- ♦ **Vasodepressor (marked hypotension without marked bradycardia)**
- ♦ **Mixed (hypotension with bradycardia)**

# Tilt Table Response in Patient with Neurally-Mediated Syncope



# Tilt Table Response in Patient with Neurally-Mediated Syncope



# **Mechanism of Tilt Table Response**


## **Physiology of head-up tilt**

- ♦ **Displaces blood from intrathoracic vascular compartment to more dependent vascular structures**
- ♦ **Results in drop in CVP, cardiac stroke volume, and systemic arterial pressure**
- ♦ **Normally activates cardiovascular and cardiopulmonary reflexes resulting in vasoconstriction and increased chronotropy and inotropy to restore systemic arterial pressure**

# **Mechanism of Abnormal Tilt Table Response**

- ♦ **In patients at risk for neurally-mediated syncope, abnormal response develops, resulting in hypotension and/or bradycardia and reproduction of syncope or near-syncope.**
- ♦ **Bezold-Jarisch reflex is thought to mediate this abnormal response through increased parasympathetic or vagal efferent activity.**

# Bezold-Jarisch Reflex



# Therapy for Neurally-Mediated Syncope

Therapy is directed at various arms of reflex:

## Afferent arm:

- Beta blockers
- Anticholinergics
- Negative inotropic agents

## Intravascular volume:

- Expanders such as fludrocortisone (mineral-corticoid)

## Efferent arm:


- Antivagal drugs such as scopolamine or  $\alpha$ -agonists

# Therapy for Neurally-Mediated Syncope


- ♦ **Beta blockers (metoprolol, atenolol, pindolol)**
- ♦ **Disopyramide (anticholinergic, negative inotropic, &  $\alpha$ -adrenergic)**
- ♦ **Florinef**
- ♦ **Midodrine (new  $\alpha$ -agonist)**
- ♦ **Permanent pacing**



# Tilt Table Testing in Patient Treated with Disopyramide for Neurally-Mediated Syncope



# Tilt Table Testing in Patient Treated with Disopyramide for Neurally-Mediated Syncope



# **Experience with Insertable Loop Recorder for Recurrent Unexplained Syncope**

- ♦ **Patient profile**
  - **Recurrent unexplained syncope**
  - **Negative tilt table & EP study**

# Patient Screening for Insertable Loop Recorder for Syncope

209 patients with syncope

H & P, ECG, tilt table test →

63 patients with no diagnosis

Presumptive  
diagnosis

146 patients

41 patients underwent EP study

Of negative EP patients, 16 had “syncope monitor”  
implanted

Krahn AD, Klein GJ, et al. Circulation.  
1995;92:1819-1824.

# Findings with Insertable Loop Recorder

16 patients  
(14-month follow-up)

Recurrent syncope (n = 15)  
(Mean occurrence  
at 4.4 months)



No syncope (n = 1)

Bradycardia  
(n = 7)

Tachycardia  
(n = 2)

Nonarrhythmic  
(n = 6)



# Syncopal Monitor Recording



Nonsustained VT

Krahn AD, Klein GJ, et al.  
Circulation. 1995;92:1819-1824.



# Syncopal Monitor Recording



## Sinus Arrest

Krahn AD, Klein GJ, et al.  
Circulation. 1995;92:1819-1824.

# Syncope Monitor Recording




## AV Block


Krahn AD, Klein GJ, et al.  
Circulation. 1995;92:1819-1824.




# Algorithm for Diagnosing Syncope



# Algorithm for Diagnosing Syncope



# Algorithm for Diagnosing Syncope



\* Performed in office setting only in the absence of bruits, a history of ventricular tachycardia, recent stroke, or recent myocardial infarction.

Linzer M, Yang EH, Estes M, et al. Ann Intern Med. 1997;127:76-86

# **Role of Permanent Pacing in Syncope Management**

## **Indications for permanent pacing:**

**Sinus node dysfunction  
(documented symptomatic bradycardia)**

**Carotid sinus hypersensitivity  
> 3 sec. of asystole or recurrent syncope with  
hypersensitive cardio-inhibitory response**

**Bifascicular block with intermittent complete heart block**

**Bifascicular or trifascicular block with intermittent type II**

**2nd degree AV block**

# **Role of Permanent Pacing in Syncope Management**

## **Indications for permanent pacing:**

- ♦ **Bifascicular or trifascicular block with syncope without other identifiable causes of syncope**
- ♦ **Markedly prolonged HV interval ( $> 100$  msec.) in asymptomatic patients**
- ♦ **Prolonged HV interval ( $> 80$  msec.) with syncope without other identifiable causes of syncope**
- ♦ **Demonstrable infra-Hisian or intra-Hisian block**
- ♦ **Neurally-mediated syncope where pacing is effective**